XXXX : a serious clinical problem and potential solution.

@entity1 @entity882 @entity1423 @entity117 @entity49 @entity10269
@entity882 ( @entity882 ) is an unusual but serious complication of heparin therapy. Twenty-five @entity1 (13 @entity1 and 12 @entity1 ) had @entity882 and @entity49 1 to 10 days (mean, 6.3 days) after the start of heparin administration. The vessels in the affected extremity had been entered for catheterization, arteriography, or passage of a balloon counterpulsation device in 19 of the 25 @entity1 . In vitro @entity1423 with heparin was seen in all @entity1 . Additional studies were performed to see whether other lots or sources of heparin also produced in vitro aggregation. Four separate lots of beef lung heparin, commercial heparin from porcine intestinal mucosa, and two types of low molecular weight heparin were all highly stimulatory in this system. However, @entity10269 , a heparinoid, did not induce aggregation in any of 13 @entity1 plasmas tested. Inhibition of @entity1423 by @entity117 was also examined. @entity117 abolished in vitro aggregation in 9 of 16 cases and decreased the degree of aggregation from 85% to 55% (p = 0.02) in the remaining seven cases. We conclude that in @entity1 with @entity882 @entity1423 is equally induced by beef lung, porcine intestinal, and some forms of low molecular weight heparin. @entity10269 does not stimulate @entity1423 in plasma from these @entity1 in vitro. Finally, there may be a role for @entity117 in treating @entity1 with @entity882 .
